Friend or foe? The proteasome in combined cancer therapy
Dennis Sohn1, Gudrun Totzke, Klaus Schulze-Osthoff
1University of Düsseldorf, Institute of Molecular Medicine, Universitätsstrasse 1, Düsseldorf, Germany.
Abstract:
The proteasome is a multicatalytic enzyme complex that is responsible for degradation of the vast majority of intracellular proteins. Thus, it is involved in diverse cellular processes such as proliferation, differentiation and apoptosis. Especially its latter function yielded in the development of specific proteasomal inhibitors which have recently entered clinical trials due to their tremendous apoptosis-inducing capability. However, several recent studies including ours provided substantial evidence that a combined treatment of tumors with apoptosis-inducing agents and proteasomal inhibitors might even cause adverse effects leading to a prolonged survival of tumor cells. Based on our model of a biphasic role for the proteasome in apoptosis, we believe that a successful combat of tumors that relies on a combinational therapy with proteasomal inhibitors requires careful evaluation of several critical aspects in order to avoid a friend becoming a foe.
Insights
Proteasome inhibitors can induce apoptosis in cancer cells, but combining them with other treatments may prolong tumor cell survival. Careful evaluation is needed to avoid adverse effects from proteasome inhibitor combination therapy.
Area of Science:
- Cellular Biology
- Biochemistry
- Cancer Research
Background:
- The proteasome is crucial for intracellular protein degradation, regulating cell proliferation, differentiation, and apoptosis.
- Proteasome inhibitors are developed for cancer therapy due to their apoptosis-inducing potential and are in clinical trials.
Purpose of the Study:
- To investigate the biphasic role of the proteasome in apoptosis.
- To evaluate the efficacy and potential adverse effects of combined proteasome inhibitor therapy in tumors.
Main Methods:
- The study likely involved in vitro or in vivo experiments analyzing proteasome function and apoptosis.
- Analysis of tumor cell survival under combined treatment conditions.
Main Results:
- Evidence suggests that combining proteasome inhibitors with apoptosis-inducing agents can lead to adverse effects.
- Tumor cells may exhibit prolonged survival under such combined treatments.
Conclusions:
- The proteasome plays a complex role in apoptosis, with potential for both therapeutic benefit and harm.
- Successful combination therapy involving proteasome inhibitors requires careful consideration of their biphasic effects to prevent negative outcomes.
More Related Videos
08:08Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Related Concept Videos
02:18The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:18The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:13The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...